Dr. Patel on Combination Chemotherapy and Immunotherapy in Lung Cancer

Partner | Cancer Centers | <b>University of Chicago Medicine Comprehensive Cancer Center</b>

Jyoti Patel, MD, professor of medicine, director, Thoracic Oncology, University of Chicago School of Medicine, discusses combination chemotherapy and immunotherapy in patients with lung cancer.

Jyoti Patel, MD, professor of medicine, director, Thoracic Oncology, University of Chicago School of Medicine, discusses combination chemotherapy and immunotherapy in patients with lung cancer.

There are a number of promising ongoing clinical trials combining chemotherapy and immunotherapy in lung cancer, says Patel.

In a phase III trial, the combination of pembrolizumab (Keytruda) with carboplatin and pemetrexed demonstrated a significantly higher response rate than chemotherapy alone, as well as an overall survival benefit. This combination led to the May 2017 FDA approval for patients as a frontline treatment.